Malignant Ciliated Muconodular Papillary Tumors of the Lung: A Case Report

2021 ◽  
pp. 106689692098835
Author(s):  
Feng Wang ◽  
Ming-Hong Shen ◽  
Dan Cao ◽  
Jing-Huan Lv
Keyword(s):  
Benign Neoplasm ◽  
Basal Cells ◽  
Mucous Cells ◽  
Cytokeratin 7 ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Malignant Case ◽  
Peripheral Lung ◽  
Transcription Factor 1 ◽  
Columnar Cells

Ciliated muconodular papillary tumors (CMPTs) are rare peripheral lung lesions, characterized by papillary architecture and ciliated columnar cells admixed with mucous cells and basal cells. Only about 50 cases have been reported to date and is categorized as a benign neoplasm. In this article, we report an extremely rare case of 79-year-old man with a CMPT that developed in his right upper lobe. The central region of the tumor showed features of classic CMPT, while marginal area of the tumor showed the characteristics of invasive lung cancer. In central classic CMPT region, the ciliated, basal, and mucous cells were positive for thyroid transcription factor-1, cytokeratin 7 (CK7), and NapsinA. Basal cells were positive for CK5/6 and p40. Mucous cells were weakly positive for MUC2 and MUC5AC. However, CK5/6 and p40 were negative in the peripheral malignant area. Both of the benign and malignant regions had an EGFR driver mutation in exon 21. We concluded that this tumor was an extremely rare malignant case of CMPT.

Immunohistochemical Analysis of Lung Carcinomas With Pure or Partial Bronchioloalveolar Differentiation

2004 ◽  
Vol 128 (4) ◽  
pp. 406-414
Author(s):  
G. Peter Sarantopoulos ◽  
Dorina Gui ◽  
Peter Shintaku ◽  
Longshen Hong ◽  
Ya-Ying Wang ◽  
...  
Keyword(s):  
Transcription Factor ◽  
World Health Organization ◽  
Immunohistochemical Staining ◽  
World Health ◽  
Cytokeratin 20 ◽  
Cytokeratin 7 ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Health Organization ◽  
Transcription Factor 1

Abstract Context.—In 1999, the World Health Organization redefined bronchioloalveolar carcinomas (BACs) as those neoplasms with only a pure lepidic growth pattern and no invasion. Objectives.—The present study examined 45 lung cancers with a BAC component (1) to determine whether these tumors would be classified as BACs by current World Health Organization standards, (2) to quantitate the BAC component within these tumors, and (3) to see if phenotypic differences exist between the so-called invasive and noninvasive regions of these tumors. Design.—Retrospective review of hematoxylin-eosin–stained slides and classification of histologic grade, tumor subtype, and percentage of pure BAC pattern, with further characterization by immunohistochemical staining for thyroid transcription factor 1, cytokeratin 7, cytokeratin 20, and Ki-67 antibodies. Results.—Only 7 (15.6%) of the 45 tumors examined could be classified as BAC by current strict World Health Organization criteria. Those tumors, classified as nonmucinous and mixed, showed similar immunohistochemical staining for cytokeratin 7, cytokeratin 20, and thyroid transcription factor 1; mucinous tumors showed disparate staining. Significant differences in immunohistochemical staining and tumor cell proliferation were seen for the regions of tumors designated as lepidic, infiltrative, and leading edge and for the regions of tumors with different histologic grades (ie, well, moderately, and poorly differentiated). Conclusions.—Nonmucinous and mixed BACs are phenotypically similar and show identical immunohistochemical staining patterns; mucinous tumors, on the other hand, show disparate immunohistochemical staining. Pulmonary neoplasms designated as adenocarcinomas with a BAC component represent a heterogenous group with a range of cell types, differentiation, growth, and immunophenotypes. Within an individual neoplasm, there are regional differences in these parameters as well.

Small Cell Carcinoma of the Renal Pelvis and Ureter: Clinicopathologic and Immunohistochemical Features

2011 ◽  
Vol 135 (12) ◽  
pp. 1565-1569 ◽  
Author(s):  
Ross J Miller ◽  
Sten Holmäng ◽  
Sonny L Johansson ◽  
Subodh M Lele
Keyword(s):  
Transcription Factor ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Small Cell ◽  
Cytokeratin 20 ◽  
Cytokeratin 7 ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

Context.—Small cell carcinoma (SCC) of the renal pelvis and/or ureter is very rare, with only case reports published in the literature. Objective.—To describe the clinicopathologic and immunohistochemical findings in the largest series to date. Design.—A review of a regional cancer registry identified 10 cases diagnosed as SCC from 930 patients with renal pelvic and/or ureteral cancer from 1971 to 1998. The original slides, demographics, treatment, and clinical outcome were reviewed. Representative sections were immunostained for AE1/AE3, cytokeratin 7, cytokeratin 20, CD56, synaptophysin, chromogranin, and thyroid transcription factor 1. Results.—Of the 10 cases, 5 were pure SCC, 2 were mixed (SCC and urothelial carcinoma), 2 were reclassified as poorly differentiated squamous carcinoma, and 1 was reclassified as urothelial carcinoma. The patients with SCC had an age range of 50 to 80 years (median, 72 years) with a female to male ratio of 2.5∶1. All patients had non–organ confined disease. Five of 7 patients died of disease; 4 of those 5 had been clinically followed (median survival, 23 months) and 1 was diagnosed at autopsy. The SCC cases revealed positive staining of the SCC component as follows: AE1/AE3 (7 of 7), CD56 (7 of 7), synaptophysin (6 of 7), thyroid transcription factor 1 (5 of 7), chromogranin (4 of 7), and cytokeratin 7 (1 of 7). None were positive for cytokeratin 20 (0 of 7). Conclusions.—SCC of the renal pelvis/ureter is seen in a predominately female population in Sweden, is clinically aggressive, and has poor survival when presenting at an advanced stage in patients only treated by surgery. An immunostain panel serves as a useful adjunct in classifying these tumors.

scholarly journals Colon Cancer With Metastatic Involvement of the Thyroid Incidentally Found at Excision of Parathyroid Adenoma

2021 ◽  
pp. 014556132110280
Author(s):  
Thaddeus J. Sullivan ◽  
Fayez Chahfe
Keyword(s):  
Colon Cancer ◽  
Parathyroid Adenoma ◽  
Cytokeratin 20 ◽  
Cytokeratin 7 ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Primary Colon Cancer ◽  
Primary Colon ◽  
Metastatic Involvement ◽  
Transcription Factor 1

Metastatic disease from primary colon cancer in the thyroid is rare. The authors have submitted such a case. What makes this case particularly unusual is that it was in a man. 80% of such cases are in women. It has been speculated that there may be a humoral component. What is even more unique in this case is that it was found during the workup of a symptomatic parathyroid adenoma. The diagnosis was confirmed with immunochemistry using markers Cytokeratin 20 (CK20), Cytokeratin 7 (CK7), and Thyroid Transcription Factor 1 (TTF-1) .

Expression of Thyroid Transcription Factor-1 in Congenital Cystic Adenomatoid Malformation of the Lung

2000 ◽  
Vol 3 (5) ◽  
pp. 455-461 ◽  
Author(s):  
Raffaella A. Morotti ◽  
Maria C. Gutierrez ◽  
Fred Askin ◽  
Sherri A. Profitt ◽  
Susan E. Wert ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Epithelial Cells ◽  
Gestational Age ◽  
Congenital Cystic Adenomatoid Malformation ◽  
Type Ii Cells ◽  
Type Ii ◽  
Basal Cells ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

Congenital cystic adenomatoid malformation (CCAM) is an abnormality of branching morphogenesis of the lung. CCAM types 1, 2, and 3 exhibit a cellular composition that is different from that of CCAM type 4 when evaluated with bronchiolar and alveolar cell markers. Thyroid transcription factor 1 (TTF-1) regulates early lung development. To evaluate the potential role of TTF-1 in the development of CCAM, TTF-1 expression in CCAM was compared to that of fetal lungs at varying gestational ages. Twenty-three CCAM cases (17 type 1, two type 2, two type 3, and two type 4) and 11 fetal lungs (3 pseudoglandular, 4 canalicular, and 4 terminal sac stages) were analyzed using a rabbit polyclonal antiserum to rat TTF-1. Nuclear staining for TTF-1 was observed in ciliated and nonciliated cells of the bronchial and bronchiolar epithelia and in cells lining the distal air spaces by 12 weeks gestational age. By mid-gestation, proximal bronchial cells were TTF-1 negative, except for the basal cells, while TTF-1 staining was maintained in distal bronchiolar and alveolar cells. TTF-1 expression decreased in both bronchial, bronchiolar, and alveolar epithelia with advancing gestational age and cytodifferentiation. At term, TTF-1 expression persisted in a few bronchial and bronchiolar basal cells and in all alveolar type II cells, whereas type I cells were negative. In CCAM, TTF-1 was detected in the nuclei of epithelial cells lining the cysts. TTF-1 was expressed in a majority of the bronchiolar-like epithelial cells of the cysts in CCAM types 1, 2, and 3, where almost 100% of the cells were TTF-1 positive. In contrast, TTF-1 expression in the alveolar-like epithelium of CCAM type 4 cysts was restricted to type II cells and only 30%–60% of the lining cells were TTF-1 positive. These results support the hypothesis that CCAM types 1, 2, and 3 reflect abnormalities in lung morphogenesis and differentiation that are distinct from those for CCAM type 4. The role played by TTF-1 in the development of CCAM, if any, is not clear.

Sign in / Sign up

Export Citation Format

Share Document